Scandal-ridden PIP implant firm had been on FDA's radar since 2000
This article was originally published in Clinica
Executive Summary
The company at the heart of the recent French silicone breast implant furore, Poly Implant Prosthèse (PIP), had given the US FDA cause for concern as far back as 2000 when an agency inspection of the firm's facility in La Seyne-sur-mer revealed manufacturing and quality control issues.